

Meeting of the Risk Communication Advisory Committee

March 5 - 6, 2018

FINAL MEETING ROSTER

RISK COMMUNICATION ADVISORY COMMITTEE MEMBERS

Chairperson**Susan J. Blalock, Ph.D., M.P.H.**

Expertise: Pharmacy
Professor Vice Chair, Division of
Pharmaceutical Outcomes and Policy
Eshelman School of Pharmacy
University of North Carolina
Chapel Hill, NC

David M. Berube, Ph.D.

Expertise: Risk Communication,
Nanotechnology
Professor, Science Communication
North Carolina State University
Raleigh, NC

W. Timothy Coombs, Ph.D.

Expertise: Crisis Communication
Professor
Department of Communication
Texas A&M University
College Station, TX

Elizabeth Howlett, Ph.D.

Expertise: Marketing
Professor
Department of Marketing & International
Business
Carson College of Business
Washington State University
Pullman, WA

Charles Lee, M.D.

Expertise: Health IT, Health Literacy
Senior Advisor
First Databank
Morrisville, NC

Cynthia Baur, Ph.D.

Expertise: Health Literacy
Endowed Chair and Director
Horowitz Center for Health Literacy
School of Public Health
University of Maryland College Park
College Park, MD

Joseph N. Cappella, Ph.D.

Expertise: Communications
Gerald R. Miller Professor of Communication
Annenberg School for Communication
University of Pennsylvania
Philadelphia, PA

Nathan F. Dieckmann, Ph.D.

Expertise: Risk Communication, Biostatistics
Research Associate Professor
School of Nursing
Oregon Health and Science University
Portland, OR

Gary L. Kreps, Ph.D.

Expertise: Health Communication
Professor
Department of Communication
George Mason University
Fairfax, VA

Andrew Pleasant, Ph.D.

Expertise: Health Literacy, Health Research
Senior Director
Health Literacy and Research
Canyon Ranch Institute
Tucson, AZ

Meeting of the Risk Communication Advisory Committee

March 5 - 6, 2018

FINAL MEETING ROSTER (cont.)

RISK COMMUNICATION ADVISORY COMMITTEE MEMBERS (cont.)

Rajiv N. Rimal, M.A., Ph.D.

Expertise: Journalism, Mass Communication
Professor and Chair
Department of Prevention/Community Health
The George Washington University
Washington, D.C.

Paul Slovic, Ph.D.

Expertise: Risk Communication
Founder and President
Decision Research
Eugene, OR

Jeannie Sneed, R.D., Ph.D.

Expertise: Food Safety, Organizational
Behavior
Principal Consultant
Sneed Consulting
Stillwater, OK

Michael S. Wolf, M.A., M.P.H., Ph.D.

Expertise: Health Communication, Health
Literacy
Professor, Medicine and Learning Sciences
Associate Division Chief – Research
Division of General Internal Medicine
Feinberg School of Medicine
Northwestern University
Chicago, IL

TEMPORARY MEMBERS

Myla Goldman, M.D.

Expertise: Neurology
*(Consultant to the FDA Peripheral and
Central Nervous System Drugs Advisory
Committee)*
Associate Professor of Neurology
University of Virginia
Charlottesville, VA

Anne Lyerly, M.A., M.D.

Expertise: Obstetrician
*(Consultant to the FDA Bone, Reproductive,
and Urologic Drugs Advisory Committee)*
Associate Director, Center for Bioethics
Research Professor, Obstetrics and
Gynecology
Professor, Social Medicine
University of North Carolina, Chapel Hill
Chapel Hill, NC

Elizabeth A. Joniak-Grant, Ph.D.

*(Patient representative and consultant to the
FDA Arthritis Drugs Advisory Committee)*
Cary, NC

Gerard Nahum, M.D., F.A.C.O.G.

*(Industry representative member of the FDA
Bone, Reproductive, and Urologic Drugs
Advisory Committee)*
Expertise: General Medicine
Vice President of Global Development,
General Medicine
Bayer HealthCare Pharmaceuticals, Inc.
Parsippany, NJ

Meeting of the Risk Communication Advisory Committee

March 5 - 6, 2018

FINAL MEETING ROSTER (cont.)

TEMPORARY MEMBERS (cont.)

Suzanne B. Robotti

*(Consumer representative member of the
FDA Drug Safety and Risk Management
Advisory Committee)*
Executive Director, DES Action USA
Founder and President
MedShadow Foundation
New York, NY

Catherine Spong, M.D.

Expertise: Obstetrician
Deputy Director
National Institute for Child Health and
Development
National Institutes of Health
Bethesda, MD

James Tracy, D.O.

Expertise: Allergy and Asthma
*(Member of the FDA Pulmonary and
Allergy Drugs Advisory Committee)*
Assistant Clinical Professor of Internal
Medicine
Creighton University School of Medicine
Managing Partner
Allergy Asthma & Immunology Associates
Omaha, NE

**Almut Winterstein, R.Ph., Ph.D.,
F.I.S.P.E.**

Expertise: Epidemiology
*(Chair of the FDA Drug Safety and Risk
Management Advisory Committee)*
Professor and Crisafi Chair
Pharmaceutical Outcomes & Policy
College of Pharmacy
University of Florida
Gainesville, FL

FDA PARTICIPANTS

Jodi Duckhorn

Director
Risk Communication Staff
Office of Planning
Office of the Commissioner
FDA

Christine P. Nguyen, M.D.

Deputy Director for Safety
Division of Bone, Reproductive, and Urologic
Products
Office of Drug Evaluation III
Office of New Drugs
Center for Drug Evaluation and Research
FDA

Meeting of the Risk Communication Advisory Committee

March 5 - 6, 2018

FINAL MEETING ROSTER (cont.)

FDA PARTICIPANTS (cont.)

Lynne P. Yao, M.D.

Director
Division of Pediatric and Maternal Health
Office of Drug Evaluation IV
Office of New Drugs
Center for Drug Evaluation and Research
FDA

Lee Zwanziger, Ph.D.

Designated Federal Officer
Risk Communication Staff
Office of Planning
Office of the Commissioner
FDA

GUEST SPEAKERS

Kayte Spector-Bagdady, J.D.,**MBioethics**

Assistant Professor, Department of Obstetrics
and Gynecology
Chief, Research Ethics Service, Center for
Bioethics & Social Sciences
University of Michigan Medical School
Ann Arbor, MI

Jamie Zahlaway Belsito

(Patient perspective)

Founder
Effie's Grace, LLC
Boston, MA

Elizabeth Conover, M.S., APRN

Genetic Counselor and Nurse Practitioner
Director
Mother to Baby Nebraska
Associate Professor
University of Nebraska Medical Center
Omaha, NE

Michael F. Greene, M.D.

Representative, The American College of
Obstetricians and Gynecologists
Professor of Obstetrics, Gynecology and
Reproductive Biology
Harvard Medical School
Chief of Obstetrics
Massachusetts General Hospital
Boston, MA

Traci J. Lee, Pharm.D.

(Industry perspective)
Director, Labeling
Global Regulatory Affairs
GlaxoSmithKline
Philadelphia, PA

Jennifer Namazy, M.D.

Representative, Vaccines and Medications in
Pregnancy Surveillance System (VAMPSS)
Physician, Allergy and Immunology
Scripps Clinic Medical Group
San Diego, CA

Meeting of the Risk Communication Advisory Committee

March 5 - 6, 2018

FINAL MEETING ROSTER (cont.)

GUEST SPEAKERS (cont.)

Laura E. Riley, M.D.

Representative, The American College of
Obstetricians and Gynecologists
Charles Montraville Green and Robert
Montraville Green Associate Professor
Obstetrics, Gynecology and Reproductive
Biology
Harvard Medical School
Vice Chair, Obstetrics
Massachusetts General Hospital
Boston, MA

FDA SPEAKERS**Malcolm J. Bertoni, M.S.**

Associate Commissioner for Planning
Director of the Office of Planning
Office of the Commissioner
FDA

Leyla Sahin, M.D.

Senior Medical Officer
Division of Pediatric and Maternal Health
Office of Drug Evaluation IV
Office of New Drugs
Center for Drug Evaluation and Research
FDA

Katherine L. Wisner, M.S., M.D.

Norman and Helen Asher Professor
Professor of Psychiatry and Behavioral
Sciences and Obstetrics and Gynecology
Director, Asher Center for the Study and
Treatment of Depressive Disorders
Feinberg School of Medicine
Northwestern University
Chicago, IL

Catherine Roca, M.D.

Medical Officer
Division of Pediatric and Maternal Health
Office of Drug Evaluation IV
Office of New Drugs
Center for Drug Evaluation and Research
FDA

Lynne P. Yao, M.D.

Director
Division of Pediatric and Maternal Health
Office of Drug Evaluation IV
Office of New Drugs
Center for Drug Evaluation and Research
U.S. Food and Drug Administration
FDA

Meeting of the Risk Communication Advisory Committee

March 5 - 6, 2018

FINAL MEETING ROSTER (cont.)

FDA PLANNING COMMITTEE MEMBERS

Tammie Brent Howard, R.N.

Senior Clinical Advisor
Division of Pediatric and Maternal Health
Office of Drug Evaluation IV
Office of New Drugs
Center for Drug Evaluation and Research
FDA

Miriam Dinatale, D.O.

Maternal Health Team Leader
Division of Pediatric and Maternal Health
Office of Drug Evaluation IV
Office of New Drugs
Center for Drug Evaluation and Research
FDA

Tamara Johnson, M.D.

Maternal Health Team Leader
Division of Pediatric and Maternal Health
Office of Drug Evaluation IV
Office of New Drugs
Center for Drug Evaluation and Research
FDA

Christine Nguyen, M.D.

Deputy Director for Safety
Division of Bone, Reproductive, and Urologic
Products
Office of Drug Evaluation III
Office of New Drugs
Center for Drug Evaluation and Research
FDA

Christina Chang, M.D.

Clinical Team Leader
Division of Bone, Reproductive, and Urologic
Products
Office of Drug Evaluation III
Office of New Drugs
Center for Drug Evaluation and Research
FDA

Audrey Gassman, M.D.

Deputy Director
Division of Bone, Reproductive, and Urologic
Products
Office of Drug Evaluation III
Office of New Drugs
Center for Drug Evaluation and Research
FDA

Denise Johnson-Lyles, Ph.D.

Senior Regulatory Project Manager
Division of Pediatric and Maternal Health
Office of Drug Evaluation IV
Office of New Drugs
Center for Drug Evaluation and Research
FDA

Jeffrey N. Roberts, M.D.

Chief
Clinical Review Branch 1
Division of Vaccines and Related Product
Applications
Office of Vaccines Research & Review
Center for Biologics Evaluation and Research
FDA



Meeting of the Risk Communication Advisory Committee

March 5 - 6, 2018

FINAL MEETING ROSTER (cont.)

Leyla Sahin, M.D.

Senior Medical Officer
Division of Pediatric and Maternal Health
Office of Drug Evaluation IV
Office of New Drugs
Center for Drug Evaluation and Research
FDA

Lynne Yao, M.D.

Director
Division of Pediatric and Maternal Health
Office of Drug Evaluation IV
Office of New Drugs
Center for Drug Evaluation and Research
FDA

Jacqueline Yancy, Ph.D.

Senior Regulatory Project Manager
Division of Pediatric and Maternal Health
Office of Drug Evaluation IV
Office of New Drugs
Center for Drug Evaluation and Research
FDA